Nexstim Plc: Managers’ Transactions, Hildén
25 Abril 2024 - 5:15AM
Nexstim Plc: Managers’ Transactions, Hildén
Company Announcement, Helsinki, 25 April 2024 at 1:15 PM
(EEST)
Nexstim Plc: Managers’ Transactions, Hildén
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces
managers’ transactions as follows:
Person subject to the notification requirementName: Timo
HildénPosition: Member of the Board/Deputy memberIssuer: Nexstim
OyjLEI: 743700S7ZI0LNMHZ6Y27Notification type: INITIAL
NOTIFICATIONReference number: 59502/4/4
____________________________________________Transaction date:
2024-04-23Outside a trading venueInstrument type: FINANCIAL
INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTName of the
instrument: 2024H Nature of transaction: ACCEPTANCE OF A STOCK
OPTION (X) Linked to stock option programme
Transaction details(1): Volume: 8500 Unit price: 0 EUR
Aggregated transactions (1): Volume: 8500 Volume weighted
average price: 0 EUR
Further information is available on the website
www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO+358 50 326
4101mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB
(publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for pre-surgical mapping of the speech and motor
cortices of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Company announcement_Managers transactions
Hildén_25042024_FINAL_EN